Racivir
From Wikipedia, the free encyclopedia
Racivir
|
|
Systematic (IUPAC) name | |
4-Amino-5-fluoro-1-[(2S,5R)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one | |
Identifiers | |
CAS number | ? |
ATC code | ? |
PubChem | |
Chemical data | |
Formula | C8H10FN3O3S |
Mol. mass | 247.25 g/mol |
Pharmacokinetic data | |
Bioavailability | ? |
Metabolism | ? |
Half life | ? |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status | |
Routes | ? |
Racivir is an experimental nucleoside reverse transcriptase inhibitor (NRTI), developed by Pharmasset for the treatment of HIV.[1]
[edit] References
- ^ AIDSmeds.com - Racivir. Retrieved on 2008-03-21.
|